MGH has been at the forefront of many scientific advances in treatments for depression.
Dr. Andrew Nierenberg graduated from the Albert Einstein College of Medicine of Yeshiva University, Bronx, N.Y., and completed his residency in psychiatry at New York University/Bellevue Hospital in New York City. After completing his training, he became a Robert Wood Johnson Clinical Scholar at Yale University to study clinical epidemiology. He moved to Boston to join the faculty at Harvard to direct the affective disorders outpatient unit at McLean Hospital. In 1992, Dr. Nierenberg then joined the psychopharmacology unit at MGH, where he is currently director of the Bipolar Program, associate director of the DCRP, director of the MGH Clinical Research Program support and education units, and professor of psychiatry at Harvard Medical School. His primary interests are in comparative effectiveness studies of mood disorders and development of interventions to treat mood disorders. In 2013, Dr. Nierenberg’s work was recognized by the Brain and Behavior Foundation Colvin Prize for Outstanding Achievement in Mood Disorders Research. He and his colleagues are currently putting together the Mood Patient-Powered Research Network (Mood PPRN) as part of the Patient-Centered Outcomes Research Institute Network (PCORInet). The main aim of the Mood PPRN is to bring together at least 50,000 patients with mood disorders who will be willing and able to participate in prospective comparative effectiveness studies and provide longitudinal data through their electronic medical record and patient-recorded outcomes. View Dr. Nierenberg’s research: http://www.ncbi.nlm.nih.gov/pubmed/?term=Nierenberg+AA+%5BAuthor%5D